Gemphire Therapeutics Inc (NASDAQ:GEMP) reached a new 52-week low during trading on Friday . The company traded as low as $0.83 and last traded at $1.73, with a volume of 169200 shares changing hands. The stock had previously closed at $1.02.
GEMP has been the subject of a number of recent analyst reports. Roth Capital reiterated a “neutral” rating and issued a $30.00 price objective on shares of Gemphire Therapeutics in a report on Friday. Raymond James downgraded Gemphire Therapeutics from an “outperform” rating to a “market perform” rating and set a $22.00 price objective for the company. in a report on Tuesday, August 7th. ValuEngine upgraded Gemphire Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 5th. Finally, Zacks Investment Research cut Gemphire Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $23.42.
The company has a quick ratio of 5.57, a current ratio of 5.57 and a debt-to-equity ratio of 0.37.
About Gemphire Therapeutics
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.
Read More: Outstanding Shares
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.